oral rigosertib

DRUG3 trials

Sponsors

Traws Pharma, Inc.

Conditions

Acute Myeloid LeukemiaCarcinoma, Squamous CellChronic Myelomonocytic LeukemiaHead and Neck NeoplasmsMyelodysplastic SyndromeMyelodysplastic Syndromes

Phase 1

Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine

CompletedNCT01926587

Traws Pharma, Inc.Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome

Start: 2013-08-31End: 2021-02-16Updated: 2021-06-16

Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer

CompletedNCT02107235

Traws Pharma, Inc.Carcinoma, Squamous Cell, Head and Neck Neoplasms

Start: 2014-01-31End: 2015-01-31Updated: 2017-06-23

Phase 2

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

CompletedNCT01904682

Traws Pharma, Inc.Myelodysplastic Syndromes

Start: 2013-07-31End: 2021-05-31Updated: 2021-06-16

Related Papers

Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.

2020-05-1217 citations

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Blood2018-11-2914 citations

Evaluation of Underlying Cause of Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes upon Oral Administration of Rigosertib: Safety and Pharmacokinetic Analysis of Rigosertib across Three Clinical Trials

Blood2018-11-293 citations

Amelioration of Rigosertib Treatment Related Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes: Implementation of Novel Dosing Regimen Derived through Pharmacokinetic Modeling in Phase 2 Study of Oral Rigosertib in Combination with Azacitidine

Blood2018-11-291 citations